Position of the Transparency Council – Remsima (infliximab)
At its meeting on 24 February 2025, the Transparency Council adopted position No. 25/2025 on the evaluation of the drug Remsima (infliximab) under the drug program B.36. “Treatment of patients with active ankylosing spondylitis (AS) (ICD-10 M45)”.